Cradle Bio Raises $73M Series B to Scale Generative AI Protein Engineering Workbench
September 2, 2026 • Source: FierceBiotech
Cradle Bio secured $73 million in Series B financing led by IVP with participation from Index Ventures and Kindred Capital to expand its wet-lab-in-the-loop protein engineering platform.
**Executive Summary (2026-09-02):** Cradle Bio secured $73 million in Series B financing led by IVP with participation from Index Ventures and Kindred Capital to expand its wet-lab-in-the-loop protein engineering platform. Source: FierceBiotech.
Technical Architecture & R&D Impact
Deployed by R&D teams at Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis, and Grifols, Cradle's fine-tuned protein language models optimize multi-parameter traits including thermostability, binding affinity, expression yield, and de-immunization in 4x fewer wet-lab rounds.
Enterprise Biopharma Procurement Takeaways
For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Funding category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.
Related Products
Published September 2, 2026
More NewsLast updated: September 2, 2026
